PHARMANUTRA S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48 EUR | 0.00% |
|
-7.69% | -14.89% |
| May. 16 | Pharmanutra S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 15 | Indices expected to rise ahead of macro data | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 226.5 | 364 | 729.9 | 601 | 542.3 | 461.5 | - | - |
| Enterprise Value (EV) 1 | 214.1 | 344.9 | 702.4 | 590.4 | 542.3 | 455.4 | 444.8 | 433 |
| P/E ratio | 26.9 x | 25.9 x | 53.1 x | 39.9 x | 42.4 x | 26.8 x | 22.5 x | 18.9 x |
| Yield | 1.97% | 1.78% | 0.94% | 1.28% | - | 1.84% | 2.07% | 2.44% |
| Capitalization / Revenue | 4.18 x | 6.2 x | 10.6 x | 7.21 x | 5.32 x | 4.08 x | 3.57 x | 3.14 x |
| EV / Revenue | 3.95 x | 5.88 x | 10.2 x | 7.08 x | 5.32 x | 4.03 x | 3.44 x | 2.95 x |
| EV / EBITDA | 16.2 x | 22.1 x | 35 x | 24.2 x | 20.5 x | 15.8 x | 13.2 x | 11 x |
| EV / FCF | 30.1 x | 33 x | 45.3 x | -66.9 x | - | 29.8 x | 23.3 x | 19.2 x |
| FCF Yield | 3.33% | 3.03% | 2.21% | -1.49% | - | 3.35% | 4.29% | 5.22% |
| Price to Book | 8.05 x | - | 16.2 x | 11.8 x | - | 7.34 x | 6.26 x | 5.41 x |
| Nbr of stocks (in thousands) | 9,681 | 9,681 | 9,681 | 9,646 | 9,616 | 9,615 | - | - |
| Reference price 2 | 23.40 | 37.60 | 75.40 | 62.30 | 56.40 | 48.00 | 48.00 | 48.00 |
| Announcement Date | 3/23/20 | 3/22/21 | 3/16/22 | 3/16/23 | 3/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 54.21 | 58.68 | 68.84 | 83.39 | 102 | 113.1 | 129.2 | 146.8 |
| EBITDA 1 | 13.2 | 15.6 | 20.08 | 24.36 | 26.48 | 28.83 | 33.77 | 39.23 |
| EBIT 1 | 12.2 | 13.66 | 18.69 | 23.04 | 23.36 | 24.9 | 29.5 | 34.93 |
| Operating Margin | 22.51% | 23.28% | 27.15% | 27.63% | 22.91% | 22.02% | 22.83% | 23.8% |
| Earnings before Tax (EBT) 1 | 12.2 | - | 18.81 | 23.42 | 23.26 | 24.85 | 28.6 | 33.05 |
| Net income 1 | 8.454 | 14.07 | 13.77 | 15.05 | 12.83 | 17.3 | 20.63 | 24.53 |
| Net margin | 15.59% | 23.98% | 20.01% | 18.04% | 12.58% | 15.3% | 15.97% | 16.71% |
| EPS 2 | 0.8700 | 1.450 | 1.420 | 1.560 | 1.330 | 1.790 | 2.133 | 2.537 |
| Free Cash Flow 1 | 7.122 | 10.46 | 15.51 | -8.819 | - | 15.27 | 19.07 | 22.6 |
| FCF margin | 13.14% | 17.83% | 22.53% | -10.58% | - | 13.5% | 14.76% | 15.4% |
| FCF Conversion (EBITDA) | 53.95% | 67.06% | 77.24% | - | - | 52.95% | 56.47% | 57.6% |
| FCF Conversion (Net income) | 84.24% | 74.35% | 112.62% | - | - | 88.25% | 92.41% | 92.12% |
| Dividend per Share 2 | 0.4600 | 0.6700 | 0.7100 | 0.8000 | - | 0.8813 | 0.9943 | 1.172 |
| Announcement Date | 3/23/20 | 3/22/21 | 3/16/22 | 3/16/23 | 3/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 32.27 | 19.16 | 36.42 | 18.97 | 20.96 | 39.93 | 20.61 | 22.85 | - | - | - | - | 29.77 |
| EBITDA 1 | 10.28 | 4.258 | 9.801 | 5.264 | 7.151 | 12.42 | 6.68 | 5.263 | 6.581 | 7.473 | 14.05 | 4.976 | 7.454 |
| EBIT 1 | 9.719 | 3.754 | 8.972 | 4.973 | 6.848 | 11.82 | 6.301 | 4.918 | 6.17 | 7.03 | 13.2 | 4.565 | 5.595 |
| Operating Margin | 30.11% | 19.6% | 24.64% | 26.22% | 32.67% | 29.6% | 30.57% | 21.52% | - | - | - | - | 18.79% |
| Earnings before Tax (EBT) 1 | 9.786 | 3.789 | 9.023 | 4.98 | 6.841 | 11.82 | 6.639 | 4.958 | 7.085 | 6.122 | 13.21 | - | 5.564 |
| Net income 1 | 7.04 | 2.885 | 6.731 | 3.486 | 4.746 | 8.232 | 4.607 | 2.209 | 5.431 | 1.801 | 7.232 | - | 3.101 |
| Net margin | 21.81% | 15.06% | 18.48% | 18.38% | 22.64% | 20.62% | 22.35% | 9.67% | - | - | - | - | 10.42% |
| EPS 2 | 0.7300 | 0.3000 | - | 0.3600 | 0.4900 | 0.8500 | 0.4800 | 0.2300 | 0.5600 | 0.1900 | 0.7500 | - | 0.3200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/6/21 | 3/16/22 | 3/16/22 | 5/9/22 | 9/14/22 | 9/14/22 | 11/7/22 | 3/16/23 | 5/16/23 | 9/11/23 | 9/11/23 | 11/6/23 | 3/15/24 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 12.4 | 19.1 | 27.6 | 10.6 | - | 6.13 | 16.7 | 28.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 7.12 | 10.5 | 15.5 | -8.82 | - | 15.3 | 19.1 | 22.6 |
| ROE (net income / shareholders' equity) | 32.2% | 42.7% | 33.3% | 31.3% | - | 28.4% | 28.4% | 28.1% |
| ROA (Net income/ Total Assets) | 18.7% | 23.3% | - | 17.5% | - | 14.1% | 15.4% | 16.8% |
| Assets 1 | 45.17 | 60.29 | - | 85.76 | - | 122.7 | 134 | 146 |
| Book Value Per Share 2 | 2.910 | - | 4.650 | 5.270 | - | 6.540 | 7.670 | 8.880 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 4.87 | 1.33 | 4.9 | 22.9 | - | 3.33 | 3.17 | 3.43 |
| Capex / Sales | 8.99% | 2.26% | 7.12% | 27.45% | - | 2.95% | 2.45% | 2.34% |
| Announcement Date | 3/23/20 | 3/22/21 | 3/16/22 | 3/16/23 | 3/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
48
EUR
Average target price
80.33
EUR
Spread / Average Target
+67.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.89% | 502M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- PHN Stock
- Financials Pharmanutra S.p.A.
